Innovation

NUCLEIC ACID NANOTUBE LIQUID CRYSTALS AND USE FOR NMR STRUCTURE DETERMINATION OF DETERGENT-SOLUBILIZED MEMBRANE PROTEINS

Dana-Farber Cancer Institute
posted on 09/16/2011

Scientists at the Harvard Medical School and the Dana-Farber Cancer institute have have discovered how to make DNA nanotubes of a uniform length that will self-assemble into liquid crystals. A solution comprising liquid crystalline DNA nanotubes is resistant to detergent and enables liquid-crystal NMR spectroscopy of membrane proteins solubilized in detergent. The DNA nanotube liquid crystals can be manufactures on a large-scale to achieve economies of scale, and then sold in aliquots to solution NMR spectroscopists across the world interested in solving the structure of clinically-relevant membrane proteins that can be the focus of structure based drug design.

Current problems with the state of NMR for membrane proteins:
? Membrane-embedded proteins are not readily amenable to existing crystallization methods. Solution NMR can be used to obtain structural information without the need for crystallization ? but this requires that proteins are solubilized in detergents. This limits the practicality of this approach to relatively small membrane associated proteins.
? It is believed that ~30% of all expressed polypeptides are membrane associated, and G-protein-coupled receptors (GPCRs) and ion channels, which are integral membrane proteins, comprise more thant 50% of human drug targets (see market indicators page).

How this invention will solve this problem:
? Makes possible the accurate measurement of residual dipolar couplings (RDCs) for a wide array of detergent solubilized proteins. This will facilitate the de novo NMR structure determination of large membrane proteins that cannot be determined using current techniques.
? This could potentially extend the size limit for solution-NMR based structure determination of membrane proteins ? making it possible to determine the structures of larger membrane proteins that are good drug targets.

How it would be sold as a product:
? Sold as a consumable solution that everyone running an NMR spec would use to determine membrane structure

Use of solution NMR in Drug Discovery
? Used in support of structure-based drug design, in which the 3-D structure of a drug target interacting with small molecules is used to guide drug discovery
? NMR is also used upstream in the drug discovery process to determine how a new drug will bind with its target molecule, optimizing leads, and as a component of the screening process

The increasing use of NMR:
? NMR spectroscopy sales are estimated at $350-400 million annually
? Demand for drug discovery applications is estimated to grow at an average of 10% per year


Innovation Details
 

File Number: 1103 

Web site: http://n/a

Other Information:

Investigator(s)
William Shih

Contact
Eric J. Stevenson, Ph.D. Phone: (617) 632-5621 Fax: (617) 632-4012 eric_stevenson@dfci.harvard.edu


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact Tony delCampo at Dana-Farber Cancer Institute for more information.

Request more info via email request more info
People

Case Manager:

Tony  delCampo Tony delCampo

Innovations (0)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

8,771 members 16,654 innovations 159 organizations

Browse

Linda L. Restifo, M.D., Ph.D. - University of Arizona

"I want to say again how happy I am about the iBridge Network mechanism. This seems ideal for NeuronMetrics and I'm very pleased we will be part of this venture."  read more...